原發性膜性腎臟病（PMN）：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

原發性膜腎臟病（PMN）概述

原發性膜性腎臟病（PMN）是成人腎病變症候群的主要病因之一。其特徵是免疫複合物沉積於腎小球基底膜上皮下表面，主要由自體抗體（尤其是抗PLA2R抗體，約佔70-80%的病例）引起，這些自體抗體靶向足細胞抗原，活化補體，破壞腎小球濾過屏障。此外，還有涉及抗THSD7A抗體的亞型，且新的抗原標靶仍在持續被發現。患者表現為緩慢進展的腎病症候群（嚴重蛋白尿、低白蛋白血症、周邊水腫、高血脂症），且血栓栓塞併發症（尤其是腎靜脈血栓症）和進行性性慢性腎臟病的風險顯著增加。診斷包括切片檢查觀察，在電子顯微鏡下可見特徵性的上皮下沉積物，以及使用抗PLA2R抗體滴度作為診斷和疾病活動度監測的生物標記。由於約三分之一的患者可自發性緩解，因此初始治療應採取保守策略，包括最佳化腎素-血管收縮素-醛固酮系統（RAAS）、血脂管理以及必要時的抗凝血治療。免疫抑制治療（傳統上以Cyclophosphamide為主要成分的Ponticelli方案或Calcineurin酶抑制劑）僅用於持續性或高危險蛋白尿。利Rituximab靶向CD20陽性B細胞以抑制自身抗體的產生，因其療效和耐受性良好，正逐漸成為一線免疫抑制治療藥物。預後因人而異，但定期監測蛋白尿和抗PLA2R抗體滴度、腎臟科醫生後續觀察以及以患者為中心的最佳化心血管和腎臟風險是長期管理的基礎。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

大公司

• Alexion Pharmaceuticals, Inc.
• Excyte Biopharma Ltd
• Climb Bio, Inc.
• Cerium Pharmaceuticals
• Vertex Pharmaceuticals Incorporated
• argenx
• BioRay Pharmaceutical Co., Ltd.
• Shanghai JMT-Bio Inc.
• Beijing Mabworks Biotech Co., Ltd.
• Biogen
• Guangdong Hengrui Pharmaceutical Co., Ltd
• BeOne Medicines
• Hoffmann-La Roche
• Everest Medicines（China）Co.,Ltd.
• Nkarta, Inc.
• Walden Biosciences
• Apellis Pharmaceuticals, Inc.
• Alpine Immune Sciences, Inc.
• Vera Therapeutics, Inc.
• Reistone Biopharma Company Limited

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Global Primary Membranous Nephropathy (PMN) Market Outlook

Thelansis's "Global Primary Membranous Nephropathy (PMN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Membranous Nephropathy treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Primary Membranous Nephropathy (PMN) Overview

Primary membranous nephropathy (PMN) is a leading cause of nephrotic syndrome in adults, characterised by immune complex deposition along the glomerular basement membrane subepithelial surface, driven predominantly by autoantibodies - most critically anti-PLA2R antibodies, present in approximately 70-80% of cases - targeting podocyte antigens, activating complement, and disrupting the glomerular filtration barrier. Anti-THSD7A antibodies account for a further subset, with additional novel antigenic targets increasingly recognised. Patients present with insidious-onset nephrotic syndrome - heavy proteinuria, hypoalbuminaemia, peripheral oedema, and hyperlipidaemia - with significant risks of thromboembolic complications, particularly renal vein thrombosis, and progressive chronic kidney disease. Diagnosis integrates renal biopsy demonstrating characteristic subepithelial deposits on electron microscopy, with anti-PLA2R antibody titres serving as both diagnostic and disease activity monitoring biomarkers. Spontaneous remission occurs in approximately one-third of patients, justifying an initial conservative approach with optimised renin-angiotensin-aldosterone system blockade, lipid management, and anticoagulation where indicated. Immunosuppressive therapy - historically cyclophosphamide-based Ponticelli regimen or calcineurin inhibitors - is reserved for persistent or high-risk proteinuria. Rituximab, targeting CD20-positive B-cells to suppress autoantibody production, has emerged as the preferred first-line immunosuppressive strategy given favourable efficacy and tolerability. Prognosis is variable; regular proteinuria and anti-PLA2R titre monitoring, nephrology surveillance, and patient-centred cardiovascular and renal risk optimisation underpin long-term management.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Alexion Pharmaceuticals, Inc.
• Excyte Biopharma Ltd
• Climb Bio, Inc.
• Cerium Pharmaceuticals
• Vertex Pharmaceuticals Incorporated
• argenx
• BioRay Pharmaceutical Co., Ltd.
• Shanghai JMT-Bio Inc.
• Beijing Mabworks Biotech Co., Ltd.
• Biogen
• Guangdong Hengrui Pharmaceutical Co., Ltd
• BeOne Medicines
• Hoffmann-La Roche
• Everest Medicines (China) Co.,Ltd.
• Nkarta, Inc.
• Walden Biosciences
• Apellis Pharmaceuticals, Inc.
• Alpine Immune Sciences, Inc.
• Vera Therapeutics, Inc.
• Reistone Biopharma Company Limited

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)